Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 8/20 | 0.37 |
| ▸ | RIPK3 | Q9Y572 | 5/20 | 0.37 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.34 |
| ▸ | AXL | P30530 | 5/20 | 0.34 |
| ▸ | TYRO3 | Q06418 | 4/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | MERTK | Q12866 | 3/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14892798 | 1.00 | MET (0.37) | METRIPK3RIPK2AXLTYRO3 | |
| SCHEMBL14892641 | 0.81 | GSK3A (0.36) | METGSK3A | |
| SCHEMBL14891732 | 0.81 | GSK3A (0.36) | METGSK3A | |
| SCHEMBL10278670 | 0.80 | MET (0.38) | METRIPK3RIPK2AXLTYRO3 | |
| SCHEMBL1911279 | 0.80 | GSK3A (0.35) | GSK3A | |
| SCHEMBL14891994 | 0.80 | GSK3A (0.35) | GSK3A | |
| SCHEMBL14891838 | 0.79 | GSK3A (0.35) | METGSK3A | |
| SCHEMBL10278589 | 0.79 | GSK3A (0.35) | METGSK3A | |
| SCHEMBL14892173 | 0.78 | MAPT (0.35) | GSK3A | |
| SCHEMBL14891672 | 0.78 | MAPT (0.35) | GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130109682-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-05-02 | — | — | US | disclosed |
| US-20130109682-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109682-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | PIM1, GSK3A, GSK3B | MET 614/4885RIPK3 610/4885RIPK2 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.